Jose Eugenio Najera

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Sapna P. Patel, Megan Othus, Yuanbin Chen et al. · New England Journal of Medicine · 2023 · 827 citations · Full text

Medicine, Oncology, Surgery +17

Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ

E. Shelley Hwang, Terry Hyslop, Thomas Lynch et al. · JAMA · 2024 · 69 citations · Full text

Medicine, Oncology, Surgery +17

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)

Rahul Aggarwal, Glenn Heller, David W. Hillman et al. · Journal of Clinical Oncology · 2024 · 49 citations · Full text

Medicine, Endocrinology, Oncology +17

Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ

Ann H. Partridge, Terry Hyslop, Shoshana M. Rosenberg et al. · JAMA Oncology · 2024 · 15 citations · Full text

Medicine, Oncology, Surgery +13

A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)

Denise A. Yardley, Robyn R. Young, Kerin B. Adelson et al. · Clinical Breast Cancer · 2021 · 11 citations

Medicine, Oncology, Pharmacology +17